ZA935723B - Hepatitis A virus vaccine. - Google Patents

Hepatitis A virus vaccine.

Info

Publication number
ZA935723B
ZA935723B ZA935723A ZA935723A ZA935723B ZA 935723 B ZA935723 B ZA 935723B ZA 935723 A ZA935723 A ZA 935723A ZA 935723 A ZA935723 A ZA 935723A ZA 935723 B ZA935723 B ZA 935723B
Authority
ZA
South Africa
Prior art keywords
hepatitis
virus vaccine
vaccine
virus
Prior art date
Application number
ZA935723A
Other languages
English (en)
Inventor
Robert A Aboud
John G Aunins
Barry C Buckland
Peter A Dephillips
Anna J Hagen
John P Hennessey Jr
Beth Junker
John A Lewis
Robert D Sitrin
Cynthia Newell Oliver
Charles J Orella
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ZA935723B publication Critical patent/ZA935723B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32451—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA935723A 1992-08-07 1993-08-06 Hepatitis A virus vaccine. ZA935723B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92687392A 1992-08-07 1992-08-07
CN93117633A CN1099798A (zh) 1992-08-07 1993-08-06 甲型肝炎病毒疫苗

Publications (1)

Publication Number Publication Date
ZA935723B true ZA935723B (en) 1995-03-22

Family

ID=36869970

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA935723A ZA935723B (en) 1992-08-07 1993-08-06 Hepatitis A virus vaccine.

Country Status (16)

Country Link
EP (1) EP0583142A2 (cs)
JP (1) JPH0748277A (cs)
CN (1) CN1099798A (cs)
AU (1) AU4450093A (cs)
CA (1) CA2103515A1 (cs)
CZ (1) CZ34795A3 (cs)
DZ (1) DZ1706A1 (cs)
FI (1) FI950567A7 (cs)
HU (1) HUT70982A (cs)
MX (1) MX9304803A (cs)
NO (1) NO950483L (cs)
PL (1) PL307402A1 (cs)
SI (1) SI9300421A (cs)
SK (1) SK18495A3 (cs)
WO (1) WO1994003589A2 (cs)
ZA (1) ZA935723B (cs)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2096650A1 (en) * 1991-09-18 1993-03-21 Keith E. Langley Hepatitis b vaccine formulation incorporating a bile acid salt
HRP950097A2 (en) * 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
NZ518945A (en) * 1997-10-09 2007-03-30 Wellstat Biologics Corp Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
HUP0302278A3 (en) 1999-04-15 2011-01-28 Pro Virus Treatment of neoplasms with viruses
KR100421386B1 (ko) * 2001-09-22 2004-03-09 엘지전자 주식회사 초고속용 유도 전동기의 회전자
US6825027B2 (en) 2001-12-10 2004-11-30 Baxter Healthcare S.A. Method of production of purified hepatitis a virus particles and vaccine preparation
AU2003229159B2 (en) 2002-04-30 2008-02-21 Oncolytics Biotech Inc. Improved viral purification methods
GB0304799D0 (en) * 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
WO2005070454A2 (en) * 2004-01-27 2005-08-04 Bharat Biotech International Limited A novel process of hepatitis a vaccine preparation
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
CN101816786B (zh) * 2010-04-30 2012-09-05 长春生物制品研究所有限责任公司 一种甲型肝炎灭活疫苗及其制备方法
CN102058882B (zh) * 2010-12-28 2012-12-26 深圳康泰生物制品股份有限公司 一种制备甲型肝炎灭活疫苗的方法
CN103013933B (zh) * 2012-12-14 2014-10-22 北京民海生物科技有限公司 人二倍体狂犬病疫苗病毒液的灭活方法
TR201902201T4 (tr) * 2015-07-23 2019-03-21 Grifols Sa İn vi̇tro üreti̇len bi̇r vi̇rüsün saflaştirilmasina yöneli̇k yöntemler ve vi̇rüse yöneli̇k klerens anali̇zi̇.
CN111511800B (zh) 2017-10-30 2023-11-28 武田药品工业株式会社 灭活脂包膜病毒的环境相容性去污剂
EP3695849A1 (en) * 2019-02-13 2020-08-19 Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH Method for extracting hepatitis a virus (hav) antigen from cell culture
CN112202628B (zh) * 2020-09-08 2022-09-02 杭州涂鸦信息技术有限公司 一种WiFi模块串口协议自动化测试系统及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296204A (en) 1978-01-25 1981-10-20 Merck & Co., Inc. Use of motionless mixer as cell culture propagator
US4164566A (en) 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
US5021348A (en) 1979-09-04 1991-06-04 Merck & Co., Inc. Attenuated hepatitis A virus
US4415670A (en) 1980-07-07 1983-11-15 Merck & Co., Inc. Motionless mixer as cell culture propagator
US4301249A (en) * 1980-07-23 1981-11-17 Merck & Co., Inc. High titer production of hepatitis A virus
NZ225583A (en) 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
JPH0751513B2 (ja) * 1988-04-28 1995-06-05 国立予防衛生研究所長 Ａ型肝炎ワクチン
CA2047041A1 (en) 1990-07-18 1992-01-19 John A. Lewis Process for purification of hepatitis-a virus capsids

Also Published As

Publication number Publication date
NO950483D0 (no) 1995-02-09
FI950567A0 (fi) 1995-02-09
CZ34795A3 (en) 1996-03-13
EP0583142A3 (cs) 1994-04-13
AU4450093A (en) 1994-02-10
PL307402A1 (en) 1995-05-15
JPH0748277A (ja) 1995-02-21
DZ1706A1 (fr) 2002-02-17
MX9304803A (es) 1994-05-31
SI9300421A (en) 1994-06-30
SK18495A3 (en) 1995-11-08
HUT70982A (en) 1995-11-28
HU9500417D0 (en) 1995-04-28
EP0583142A2 (en) 1994-02-16
NO950483L (no) 1995-04-07
FI950567A7 (fi) 1995-04-05
CN1099798A (zh) 1995-03-08
CA2103515A1 (en) 1994-02-11
WO1994003589A3 (en) 1994-03-31
WO1994003589A2 (en) 1994-02-17

Similar Documents

Publication Publication Date Title
AU2371692A (en) Recombinant hepatitis a virus vaccine
ZA935723B (en) Hepatitis A virus vaccine.
HUP9801242A3 (en) Hepatitis b vaccine
IL122589A0 (en) Vaccines against hepatitis c
OA09888A (en) HLA-restricted hepatitis B virus CTL epitopes.
GR3022174T3 (en) Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a.
GB9208545D0 (en) Virus resistant plants
AU5679394A (en) Hepatitis b virus vaccines
ZA956106B (en) A polynucleotide herpes virus vaccine
EP0595970A4 (en) IMPROVED VACCINE.
FI934777A0 (fi) Multipel hepatitis b virus ytproteiner som bildar partiklar
EP0533263A3 (en) A multivalent hepatitis b virus vaccine
HU9203976D0 (en) Vaccine based on modified herpes virus
AU688259B2 (en) Hepatitis C virus peptides
IL106609A0 (en) Hepatitis a virus vaccine
ZA926441B (en) HLA-restricted hepatitis B virus CTL epitopes.
GB9124696D0 (en) Hepatitis c virus
HU0400424D0 (en) Hepatitis virus vaccines
IE880242L (en) Hepatitis b virus antigens.
EP0621893A4 (en) Vaccines against the cat's leukemia virus.
SI0810877T1 (en) Hepatitis b vaccine
GB9305710D0 (en) Viral vaccines
GB9324964D0 (en) Viral vaccines
ZA912581B (en) Hepatitis c virus epitopes
GB9104903D0 (en) Viral vaccines